Developing new chemical tools for cancer treatment
Official title: Chemical Probes and Drug Discovery
Funded at Wistar Institute · NIH-11085170 · Data updated 2026-11-12
This study is exploring new ways to create drugs that can help fight cancer by breaking down a specific protein linked to the disease, aiming to find better treatments for patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 11, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $339,305 |
| NIH project number | 5P01CA269043-03 |
| Project ID | NIH-11085170 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers associated with the EBNA1 protein or those who may benefit from novel anti-cancer agents.
✕Less likely to help
Patients with cancers not related to the EBNA1 protein or those who do not respond to targeted therapies may not benefit from this research.
What this research studies
This research focuses on creating innovative chemical probes and drug candidates aimed at degrading specific proteins involved in cancer progression, particularly targeting the EBNA1 protein associated with certain cancers. The team will utilize advanced techniques in assay development and synthetic chemistry to screen and develop these new compounds. By comparing the effects of protein degradation versus traditional inhibition methods, the research aims to identify more effective treatments for cancer patients. The approach includes using small DNA oligos and E3 ligase recruiting molecules to enhance the efficacy of the drug candidates.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that specifically target and degrade harmful proteins, potentially improving patient outcomes.
How similar studies have gone: Other research has shown promise in using targeted protein degradation as a therapeutic strategy, indicating that this approach could be a significant advancement in cancer treatment.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Salvino, Joseph M — Wistar Institute
- Study coordinator: Salvino, Joseph M
Related research
Other NIH-funded projects on the same topics.
-
Immunomodulation to Fight Cancer Spread
A cancer-focused training opportunity to learn how tumors and the immune system interact during cancer spread and use that knowledge to develop new immunotherapies.
-
Broadly neutralizing nanobodies to improve HIV therapy
Researchers are developing tiny antibodies called nanobodies to target HIV in new ways that could make treatments easier and more effective for people living with HIV.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Epitope-engineered stem cells to enable HIV cure with targeted CAR-T therapy
A patient-focused plan to use a person’s own stem cells, edited to resist HIV and paired with specialized CAR-T cells, to clear HIV reservoirs.
-
Comprehensive bioinformatics support for cancer research at a leading cancer center
A cancer center-wide bioinformatics program helps researchers analyze data, build reusable data resources, and apply computational methods to cancer studies.
-
Refocusing HIV antibodies to target parts that block many strains
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.